Is the severity of microvascular dysfunction due to compartment syndrome diminished by the systemic application of CO-releasing molecule-3?
CORM-3 displays a potent protective/anti-inflammatory action in an experimental model of CS, suggesting a potential therapeutic application to patients at risk of developing CS.
These results suggest that the hormone related molecular pathways that drive cancer progression might be different in AC and DC. The decrease in steroid synthesis related enzymes, together with up-regulation of the BCAR1-Src pathway, emphasizes the biological particularities of DC.